Striving for Consensus on the Management of ALK-Positive Lung Cancer

1

Introduction

00:00 • 2min

2

The Evolution of Alk Rearrangements

01:42 • 2min

3

Immunotherapy in Lung Cancer

03:42 • 3min

4

The Oncogen Addiction of Non-Smokers

06:47 • 3min

5

Do You Use Alk and IOs in Non-Spel Cell Lung Cancer?

09:26 • 2min

6

Alk Inhibitors in the Adjuvant Setting - Any Thoughts?

11:15 • 2min

7

Adora

12:50 • 3min

8

Adjuvant or Consolidation TKI After Radio Chemotherapy?

15:21 • 3min

9

Oncogenic Oncology - Is There a Targeted TKI?

18:27 • 3min

10

Is Targeted Therapy First Line in Metastatic Disease?

21:56 • 2min

11

Oncogene-Driven Lung Cancer and Pregnancy

23:48 • 2min

12

Pathways to Motherhood to Cover Everything

25:38 • 2min

13

Breast Cancer Study - What Does It Mean to Be in Good Health?

27:33 • 2min

14

ALC Inhibitor

29:58 • 2min

15

Do You Have ALC Positive Lung Cancer?

31:54 • 5min

16

Is There a Difference Between on Target Resistance and Off Target Resistance?

36:44 • 2min

17

RNA Based Sequencing Can Be Helpful for Fusion Detection

38:17 • 2min

18

What Do We Know About Alk Outside of Lung Cancer?

39:52 • 3min

19

Is There a Repetition Mutation Testing in EGFR?

43:00 • 2min

20

EGFR Mutant Lung Cancer

45:25 • 2min

21

P53 and Non-Small Cell Lung Cancer

47:03 • 2min

22

Alk Inhibitor

48:46 • 4min

23

Oncology - What's the Big Elephant in the Room?

52:36 • 4min

24

Alc Inhibitor Response Rates Compared to Cresontinib

56:15 • 5min

25

The Hazard Ratios Tend to Be a Little Bit Different in Breast Cancer and Colorectal Cancer

01:01:45 • 2min

26

The Structure of Lorelatt Nib

01:03:30 • 2min

27

Is There a Difference in CNS Activity of Second Generation Alkin Inhibitors?

01:05:08 • 2min

28

Electinib or Lore Latinib?

01:07:05 • 2min

29

The Neurocognitive Effects of Lore Latinib

01:09:17 • 2min

30

Is the Latinib the Best Choice in Patients With Brain Mats?

01:11:40 • 3min

31

The Pro and Cons of Law Latinib in Breast Cancer

01:15:07 • 3min

32

Dose Reduction in CNS Toxicity

01:18:14 • 2min

33

Do You Use Lorlatanate in Brain Metastasies?

01:20:03 • 2min

34

Gene Therapy for Non-Solar Cancer

01:22:21 • 5min

35

The Molecular Mechanism of Resistance of TKI After TKI

01:27:19 • 4min

36

Is There a Drug to Overcome Compound Mutations After Latinib Resistance?

01:31:39 • 5min

37

Oncology

01:37:04 • 2min

38

Alc Inhibitors and How to Manage Them

01:38:59 • 4min

39

The Monitoring Process for Electinib

01:42:52 • 3min

40

The Side Effects of Lolatinib

01:45:50 • 4min

41

CNS Effects and Dosage Reduction

01:49:41 • 3min

42

How Aggressive Are You About Treating Hypercholesterolemia?

01:53:08 • 2min

43

Neurocognitive Effects in Mood Issues

01:55:22 • 3min

44

Cancer

01:58:03 • 2min

45

Lung Cancer - What's Bitter?

01:59:43 • 2min

46

How to Manage Cholesterol and Weight Gain

02:01:48 • 2min

47

A 54 Year Old Woman With a Lung Mass and Brain Metastases

02:03:53 • 2min

48

CNS Surveillance in CNS Disease

02:06:03 • 2min

49

Is There a Cure for Brain Metastases?

02:08:08 • 2min

50

The Time Capsule of Clinical Trial Participation

02:09:53 • 5min

51

A Case Study of a Caucasian Female Smoking History Quit 30 Odd Years Ago

02:14:46 • 5min

52

The Lazarus Effect and Lung Cancer

02:19:57 • 5min

53

Pneumonitis - What Did You Come Up With?

02:25:09 • 2min

54

Lung Cancer - A Young Man's Story

02:26:44 • 3min